Patient-derived xenograft (PDX) models have become an indispensable tool in cancer research, largely owing to their ability to accurately re-create the biology of human tumors. PDX models, by implanting human tumor tissue in immune-deficient mice, produce tumors very similar to the original tumors, both in histopathology, genetics, and therapeutic response. An important breakthrough in the PDX model is the re-establishment of human immune system, making it possible to study similar immune responses in humans, especially in the development of immunotherapies.
The PDX models are different in that they replicate the heterogeneity and biology of human tumors and thus have a greater predictive value than cell line models. It allows scientists to gain a full picture of cancer, and to personalize drug therapies. In the field of drug screening, they give the ability to assess heterogeneity among tumors by allowing drug responses to be evaluated across a wide range of cancer types and patient-derived samples. Drug screening using PDX models can identify therapeutic targets and determine efficacy at a more translational level. This leads to a more stratified and individualized cancer treatment planning and better chances of clinical success in new drug development.
With Creative Bioarray’s advanced PDX model construction technology and years of experience, we provide our customers with comprehensive PDX model construction services to facilitate accurate and effective oncology drug screening.
Advantages of PDX models
- Preserves the genotypic and expressive diversity of the patient’s tumor tissue.
- Preserves the original tumor stroma and microenvironment.
- Accurately mirror the patient’s mechanism of tumorigenesis and development
- Accurate drug sensitivity and tolerance assessment.
Applications
- PDX models are employed in cancer biology and drug resistance studies to identify cancer-specific biomarkers.
- For discovery and evaluation of potential cancer drugs, e.g., in testing chemotherapeutics, antibody therapies, and microbial therapies.
- Provide unlimited sources of tumor cells in high-throughput screening of cancer drugs.
- Corresponding PDOs or PDXOs to test new drug therapies.
- Immunotherapy studies.
